Dialysis market dominance: DaVita and Fresenius's grip on American healthcare

On any given Tuesday morning, in Phoenix and Houston and Detroit and a thousand smaller American cities in between, roughly 560,000 people sit down in reclining chairs, have needles inserted into their arms, and spend the next three to four hours connected to a machine performing the work their kidneys can no longer do. They will return Thursday. And Saturday. And the following Tuesday. For most of them, this will continue for the rest of their lives. This is the American dialysis market — and for more than two decades, it has been the almost exclusive domain of two corporations.

DaVita and Fresenius Kidney Care together account for an estimated 71.7% of all dialysis treatments administered in the United States. No other healthcare sector of comparable scale is so thoroughly concentrated in so few hands. The two companies set clinical standards, shape physician behavior, negotiate with Medicare and private insurers simultaneously, and influence federal policy through sustained lobbying efforts that dwarf those of any competing organization in nephrology. To understand American dialysis is, in large measure, to understand these two companies — how they built their dominance, how they sustain it, and what forces are now, slowly, beginning to test it.

A DISEASE THAT CREATES ITS OWN DEMAND

End-stage renal disease is, in clinical terms, a life sentence. The kidneys — two fist-sized organs responsible for filtering roughly 200 liters of blood per day — deteriorate through a progression that is largely irreversible. Diabetes and hypertension are responsible for approximately 74% of new ESRD cases in the United States, according to the National Kidney Foundation, which means the same chronic disease epidemics driving so many other healthcare crises are also steadily filling dialysis chairs across the country. An estimated 815,000 Americans currently live with ESRD, with approximately 131,000 new patients diagnosed annually.

The only two treatments for kidney failure are dialysis and transplantation. But the U.S. transplant waitlist is brutally long — patients typically wait three to seven years for a donor kidney, and many never receive one. The result is a patient population that, once it enters the dialysis system, largely remains there. Patient turnover is driven by death and transplant, not by choice or dissatisfaction. Dialysis centers do not lose patients to competitors the way airlines lose passengers or retailers lose shoppers. This structural captivity is the bedrock on which both DaVita and Fresenius constructed their empires.

Medicare amplifies this structural reality. Under a unique provision of U.S. law, the federal government provides ESRD coverage regardless of a patient's age — the only condition for which Medicare confers this categorical entitlement. After an initial 30-month coordination period in which private insurance remains the primary payer, Medicare takes over as the principal reimbursement mechanism for virtually the entire dialysis population. According to the Clinical Journal of the American Society of Nephrology, approximately 90% of DaVita patients are covered by government programs, with roughly 68% covered specifically by Medicare or Medicare Advantage. The CY 2026 ESRD Prospective Payment System Final Rule, issued by CMS in November 2025, sets the Medicare base rate at $281.71 per dialysis treatment — a figure that, multiplied across hundreds of thousands of patients receiving approximately 156 treatments per year, yields a program expenditure the Medicare Payment Advisory Commission estimated at $8.1 billion for fee-for-service alone in its March 2025 report to Congress.

Private insurers, by contrast, reimburse at rates that research from UCLA's health economics program estimates at roughly four times the Medicare rate per session. This payer differential is the single most powerful financial dynamic in the industry: dialysis centers actively seek to maximize their commercially insured patient volume, particularly among newly diagnosed patients in the 30-month pre-Medicare window, before the inevitable transition to government rates. Both DaVita and Fresenius have built revenue optimization frameworks around this dynamic. Its implications extend into physician relationships, site selection, and corporate political strategy alike.

DAVITA: HOW A STRUGGLING COMPANY BECAME THE MARKET LEADER

DaVita's ascent to market leadership is one of the more striking corporate turnarounds in American healthcare history. The company traces its modern form to the 1999 restructuring of Total Renal Care, a financially troubled dialysis operator that rebranded and, under new leadership, pursued an acquisition strategy so aggressive it ultimately drew federal scrutiny. Over the following two decades, DaVita absorbed hundreds of independent dialysis operators, expanded into physician partnerships through joint ventures, and constructed a clinical infrastructure that now spans approximately 3,200 U.S. locations and employs roughly 69,000 people, according to CoStar Group tenant data as of March 2026.

The company generated $12.82 billion in revenue in its most recent fiscal year, with the overwhelming majority derived from U.S. dialysis operations. Its corporate structure is notably self-contained: DaVita functions simultaneously as a clinical provider, a care coordination platform, and a policy advocate. The company's integrated kidney care (IKC) platform — which encompasses predialysis chronic kidney disease management, in-center hemodialysis, home dialysis programs, and post-transplant care — is an attempt to extend DaVita's patient relationship across the entire arc of kidney disease progression, not merely the terminal phase. This upstream strategy reflects a recognition that the pure dialysis clinic model, while still enormously profitable, is increasingly subject to policy pressure and patient preference shifts that favor earlier intervention and alternative modalities.

DaVita's market position rests heavily on its physician relationship architecture. The company has, over the years, structured joint ventures with nephrologists in which physicians hold equity stakes in the clinics where their patients receive care. This model creates powerful referral loyalty — a nephrologist who co-owns the clinic has strong financial incentive to route patients there — and has been central to DaVita's ability to anchor market share in competitive geographies. According to a 2025 JAMA Health Forum study by Xia et al., physician-owned joint ventures with large dialysis chains grew from 4.6% to 23.7% of facilities between 2005 and 2019, with DaVita and Fresenius as the principal architects of this expansion. The same study found that DaVita and Fresenius increased their combined market share from 59.1% in 2005 to 77.1% by 2019, acquiring 1,425 facilities in the process.

MMCG database analysis estimates DaVita's current U.S. market share at approximately 37.8% of total industry revenue, making it the single largest dialysis provider in the country by a meaningful margin — though this lead has narrowed somewhat from its peak as Fresenius has pursued its own consolidation strategy and as independent operators have found niches in markets the national chains have not fully penetrated.

DaVita and Fresenius increased their combined market share from 59.1% in 2005 to 77.1% by 2019, acquiring 1,425 facilities in the process. — JAMA Health Forum, 2025

FRESENIUS KIDNEY CARE: THE VERTICAL EMPIRE

Fresenius Kidney Care occupies a different position in the competitive landscape — one defined less by the scale of its American clinic network than by the extraordinary vertical integration of the broader Fresenius Medical Care enterprise of which it is a part. Fresenius Medical Care AG & Co. KGaA, the German parent company listed on the NYSE as FMS, is simultaneously the world's largest provider of dialysis services and one of the largest manufacturers of dialysis equipment and consumables. This dual identity — operator and supplier — creates competitive dynamics with no direct parallel in the American dialysis market.

In the United States, Fresenius Kidney Care operates approximately 2,560 clinic locations employing around 125,000 people, according to CoStar Group data as of March 2026. The parent company globally employs nearly 194,000 across more than 3,000 locations. MMCG 'analysis estimates Fresenius Kidney Care's U.S. market share at approximately 33.9%, ranking it second to DaVita but close enough that in many individual metropolitan markets the two companies are effectively co-dominant, with the local balance determined by historical acquisition patterns and physician network affiliations rather than by any meaningful clinical differentiation.

The company's acquisition of NxStage Medical in 2019 for approximately $2 billion was a defining strategic move — one that extended Fresenius's vertical integration from dialysis equipment manufacturing directly into the home hemodialysis device market. NxStage's System One device, the leading home hemodialysis platform in the United States, is now owned by the same company that operates one-third of the country's dialysis clinics. This creates an unusual dynamic: Fresenius profits both from patients who receive in-center care at its clinics and, increasingly, from patients who use its home equipment at DaVita clinics or at independent facilities. Fresenius is, in a meaningful sense, a supplier to its own competitors.

This vertical position has only grown more strategically significant as the policy environment has shifted toward home dialysis. Fresenius's ability to offer a comprehensive equipment, supplies, and clinical support package for home hemodialysis — all from a single corporate entity — gives it a structural advantage in the transition to home modalities that DaVita, which lacks equivalent equipment manufacturing capability, cannot easily replicate. DaVita has responded by entering into a strategic agreement to expand its use of NxStage machines for its own home patients, meaning DaVita's largest competitor now supplies critical equipment through which DaVita serves its own patient population. It is a competitive arrangement of remarkable peculiarity, and it speaks to the degree to which the two companies' fates are intertwined even as they battle for market share.

Competitive Snapshot: DaVita vs. Fresenius Kidney Care (2026)

METRIC	DaVita	Fresenius Kidney Care
U.S. Clinic Locations	~3,200	~2,560
Employees	~69,000	~125,000 (U.S.)
Annual Revenue	$12.82B	Part of FMC (~€18B global)
Est. U.S. Market Share	~37.8%	~33.9%
NYSE Ticker	DVA	FMS
HQ	Denver, CO	Bad Homburg, Germany
Vertical Integration	Integrated kidney care (IKC platform)	Dialysis equipment + clinics (NxStage)
Home Dialysis Strategy	DaVita Home (HD + PD programs)	NxStage acquisition (2019)

Sources: MMCG Research; Company filings.

THE GEOGRAPHY OF DOMINANCE

The dialysis duopoly does not operate uniformly across American geography. Both companies have concentrated their densest clinic networks in regions shaped by three overlapping forces: an aging population, elevated chronic disease prevalence — particularly diabetes and hypertension — and the demographic patterns of the nation's fastest-growing metropolitan areas. Understanding the geographic distribution of each company's network illuminates not only where the competitive battle is most intense, but where each has established positions of near-monopoly local control.

California and the Pacific states represent the single largest geographic concentration of dialysis clinics in the country, driven by population scale and among the highest rates of end-stage renal disease mortality of any state, according to CDC data. Both DaVita and Fresenius maintain dense presences across the Los Angeles basin, the Central Valley, and the Bay Area — markets where competitive dynamics are acute and where physician joint venture networks have historically been the primary battleground for patient share. California has also been the most active legislative environment for dialysis regulation, with both companies lobbying heavily against state bills that would mandate increased staffing ratios and restrict reimbursement practices.

Texas presents a different kind of dominance story. The state's combination of rapidly expanding population centers — Houston, Dallas-Fort Worth, San Antonio, Austin — with persistently elevated rates of diabetes and obesity among its substantial Hispanic population creates a patient pipeline both operators have aggressively pursued. Houston in particular has seen concentrated clinic development in its outer suburban corridors, where new residential growth coincides with the demographic risk profile most associated with ESRD. According to MMCG database analysis, the Houston metropolitan area hosts one of the highest concentrations of new dialysis clinic openings of any major U.S. market over the past five years, reflecting both population growth and the underlying chronic disease burden of its communities.

Florida is arguably the most demographically favorable dialysis market in the country, and both operators have built accordingly. The state's concentration of residents aged 65 and older — in Tampa Bay, South Florida, the Space Coast, and the Panhandle — creates dialysis demand that is both high in volume and actuarially predictable. The National Kidney Foundation reports that chronic kidney disease rates rise sharply among adults over 65, making retirement-destination states like Florida structural growth markets for dialysis providers. Saturation in certain South Florida submarkets has slowed new clinic development, but the continued in-migration of retirees from the Northeast and Midwest ensures ongoing demand pressure.

The Southeast broadly — Georgia, the Carolinas, Tennessee, Alabama, Mississippi — has emerged as the fastest-expanding operational zone for both major operators, driven by demographic tailwinds and, in states like Georgia, the pronounced ESRD burden among African American communities. Black Americans develop kidney failure at approximately four times the rate of white Americans, according to the National Kidney Foundation, driven by a combination of genetic predisposition, higher rates of hypertension, and structural inequities in access to preventive care. This disparity concentrates ESRD patient volume in communities and geographies where the social determinants of health have historically gone unaddressed — a reality that creates both clinical urgency and significant questions about how the two dominant operators have engaged with those communities.

The industrial Midwest — Ohio, Michigan, Indiana, Illinois — represents one of the more consequential dialysis geographies from a public health standpoint. Urban communities in Detroit, Cleveland, and Chicago's South and West sides bear disproportionate ESRD burdens driven by decades of environmental exposure, high rates of uncontrolled hypertension, and limited access to nephrology care before the point of kidney failure. Both DaVita and Fresenius have significant Midwest footprints, though the Midwest also hosts a higher proportion of hospital-owned dialysis units relative to the Sun Belt — a structural feature that partially constrains the duopoly's market penetration in certain urban cores.

THE ANTITRUST CLOUD: HOW TWO COMPANIES LOCKED UP A MARKET

The concentration of American dialysis in two corporate entities has not gone unexamined by regulators. In 2024, the Federal Trade Commission opened a formal antitrust investigation into both DaVita and Fresenius, focusing on allegations that non-compete clauses in physician employment contracts function as anti-competitive instruments that suppress market entry and limit patient access to alternatives. The investigation centers on whether physicians employed at DaVita or Fresenius clinics are contractually barred from departing to work at competing providers or to establish independent clinics within the same geographic market — and whether those restrictions have chilled competition in ways that harm patients.

The JAMA Health Forum study by Xia et al. provides the most granular quantitative evidence yet of what consolidation has wrought on market pricing and physician behavior. The study found that approximately one-third of the U.S. population lives in areas served by only one large dialysis chain — a degree of local market monopoly that gives the dominant operator substantial pricing power over private insurers. Markets with single-chain monopoly presence showed average commercial prices per session that were $495 higher than markets with at least two competing large chains. The study also documented that the dialysis industry commands the highest markup over Medicare rates of any sector in U.S. healthcare for commercial payers, a premium that has persisted and widened through the consolidation era.

Both companies have lobbied extensively to protect the structures that sustain these dynamics. In California — the state with the most aggressive legislative scrutiny of dialysis industry practices — DaVita and Fresenius spent tens of millions of dollars over successive legislative cycles opposing ballot initiatives and bills that would have imposed staffing ratio requirements, mandated data transparency, and constrained certain reimbursement practices. The companies prevailed in most of these battles, but the political and reputational costs have been substantial, and the legislative campaigns themselves have generated a body of public disclosure about industry economics that was previously unavailable.

The MedPAC March 2025 report adds an independent government advisory layer to this picture. Among fee-for-service Medicare beneficiaries, the two large dialysis organizations accounted for approximately 75% of all facilities and treatments. The top five organizations combined controlled roughly 87% of the market. MedPAC noted an all-payer provider margin of approximately 14% in 2022 — a figure that, while lower than peak years, remains substantially above what most healthcare analysts consider competitive market margins. MedPAC has repeatedly raised questions about whether the ESRD prospective payment system adequately accounts for the market structure effects of extreme concentration.

Approximately one-third of the U.S. population lives in dialysis markets served by only one large chain — generating commercial prices $495 higher per session than contested markets. — JAMA Health Forum, 2025

THE HOME DIALYSIS QUESTION: INNOVATION OR EXISTENTIAL THREAT?

For at least a decade, the consensus view in nephrology has been that home-based dialysis — peritoneal dialysis and home hemodialysis — is the future, that patient preference for autonomy combined with supportive policy would drive a meaningful shift away from the three-times-weekly in-center model. The reality has been more complicated. Home modalities still account for a relatively modest share of total treatments in the United States, constrained by high upfront equipment costs, the training burdens placed on patients and caregivers, the clinical conservatism of nephrologists whose professional formation has centered on in-center care, and the significant infrastructure gaps that the USRDS 2024 Annual Data Report documents: 57.9% of U.S. dialysis facilities are not certified to train patients in home dialysis.

CMS's ESRD Treatment Choices (ETC) model, which provided financial incentives to clinicians who transitioned patients to home modalities or transplant, was one of the most significant policy experiments in dialysis in decades. But the ETC model had a troubling distributional problem: research published in JAMA in 2024 by Koukounas et al. found that facilities serving patients with two or more social risk factors had lower home dialysis utilization rates (14.1% versus 16.0%) and received higher financial penalties under the model (18.5% versus 11.5%). Facilities serving the highest proportions of Black patients were penalized at disproportionate rates. In December 2025, CMS terminated the ETC model, effective December 31 of that year, leaving the policy landscape for home dialysis promotion without its primary federal incentive mechanism.

Both DaVita and Fresenius have invested substantially in home programs, but their motivations and capabilities differ. Fresenius, through NxStage, possesses the most advanced home hemodialysis equipment platform in the country and has a structural interest in promoting home hemodialysis regardless of whether it occurs at a Fresenius clinic or a competitor's. DaVita's home strategy is integrated into its broader IKC platform, designed to retain patient relationships across modality transitions. The notable paradox — that DaVita has entered a supply agreement to use Fresenius-owned NxStage machines for its home patients — illustrates both the maturity of the competitive relationship between these two companies and the degree to which the market remains structured around their duopoly even in the emerging home segment.

New competitive entrants are beginning to test the home dialysis space from outside the traditional clinic model. CVS Health, having received FDA clearance for its HemoCare home hemodialysis system, represents the most credible retail-channel entrant into the space to date — one with distribution infrastructure and consumer brand recognition that no independent dialysis operator can match. The commercial rollout trajectory remains uncertain, but the entry of a company of CVS's scale signals that the home dialysis market is attracting capital and attention from outside the traditional healthcare provider ecosystem. Whether that translates into meaningful disruption of the in-center model — or whether it remains a parallel channel serving a distinct patient segment — will be among the most consequential questions in nephrology over the next decade.

DEMOGRAPHICS: THE TAILWIND THAT EXPLAINS EVERYTHING

Beneath the competitive strategy, the antitrust politics, and the clinical debates about home versus in-center care lies a demographic reality that, more than any corporate decision, determines the trajectory of American dialysis. The U.S. population is aging at a rate without historical precedent. According to the Population Reference Bureau, the cohort of Americans aged 65 and older will grow from approximately 58 million in 2022 to 82 million by 2050 — an increase of more than 40% in the population segment most vulnerable to chronic kidney disease. The CDC reports that CKD rates rise sharply among adults over 70, meaning that the aging of the Baby Boom generation is not a future phenomenon but an ongoing one, visible in new patient enrollment figures at dialysis clinics across the country right now.

Diabetes and hypertension — the two diseases responsible for nearly three-quarters of new ESRD cases — are themselves becoming more prevalent as obesity rates rise and as the dietary patterns that underlie metabolic disease remain deeply entrenched in American life. USDA tracking of dietary adherence to federal nutritional guidelines consistently shows a substantial gap between recommended and actual consumption patterns, particularly for sugar, sodium, and processed foods. The downstream effect, measured in ESRD incidence rates, is a patient pipeline that neither DaVita nor Fresenius created and neither can easily reduce.

The racial dimension of ESRD epidemiology deserves particular emphasis. Black Americans develop kidney failure at approximately four times the rate of the white population. Hispanic Americans face roughly twice the risk, driven by elevated rates of type 2 diabetes. Native Americans also experience disproportionate ESRD burden. These disparities are not merely clinical abstractions — they are population concentrations that both DaVita and Fresenius have built their growth strategies around, in the most commercially dense regions of the country. The ethics of that orientation — providing essential, life-sustaining care to vulnerable populations while earning market-rate returns on government-funded treatments — is the central moral question that critics of the for-profit dialysis model have raised, and that the Clinical Journal of the American Society of Nephrology addressed directly in a 2023 paper calling for greater corporate accountability.

According to MMCG database projections, the U.S. dialysis industry is expected to sustain a compound annual revenue growth rate of approximately 1.7% over the five years to 2030, reaching an estimated $33.8 billion in total market revenue. That is not explosive growth — the dialysis market has never been a high-growth story in the conventional sense — but it is growth that is almost entirely insulated from economic cycles, driven by biology and demography rather than consumer sentiment or discretionary spending. New patients will continue entering the system at roughly 131,000 per year. The transplant shortage will not resolve itself. And the chronic disease epidemics that feed ESRD incidence show no credible sign of meaningful near-term reversal.

ACCOUNTABILITY, REFORM, AND THE LIMITS OF MARKET CONCENTRATION

The for-profit dialysis model has generated returns for DaVita and Fresenius shareholders that would be impressive in any industry. It has also generated a sustained and growing body of critical literature questioning whether extreme market concentration, physician financial ties, and Medicare reimbursement at scale are compatible with the public health obligations of companies that provide life-sustaining treatment to vulnerable populations with no realistic alternatives.

The CJASN 2023 paper by Rosner et al. frames this tension through stakeholder theory: entities with DaVita and Fresenius's degree of market power and dependence on public funding bear heightened obligations to patients, clinicians, and the public that go beyond the conventional shareholder-primacy model. The paper notes that DaVita CEO compensation reached $73.4 million in a recent reporting period — including a multiyear equity grant — at a company where 90% of patients are covered by government programs and where the treatment itself is a medical necessity with no substitute. The juxtaposition is pointed.

What reform of this market would actually look like remains contested. More aggressive antitrust enforcement — unwinding physician joint ventures, prohibiting certain non-compete arrangements, requiring divestiture in markets where one chain holds monopoly control — would be one avenue. Expansion of the independent clinic sector, through regulatory relief and financing mechanisms targeted at new entrants, would be another. Acceleration of home dialysis adoption, reducing the dependence of patients on any particular clinic network, could partially rebalance the power dynamic between operators and patients. None of these interventions is simple, politically frictionless, or rapidly executable.

What is clear is that the status quo — two companies, exercising shared dominance over an essential medical service, operating within a payment system that has consistently rewarded consolidation — is unlikely to persist indefinitely without significant policy attention. The FTC investigation opened in 2024 may or may not produce structural remedies. The termination of the ETC model removes one lever for home dialysis promotion. The legislative environment in high-scrutiny states like California remains active. And the entry of new competitors in the home space, however uncertain their trajectories, signals that the boundaries of the dialysis market are beginning to shift in ways that neither DaVita nor Fresenius fully controls.

For now, the 560,000 Americans sitting in those chairs three times a week do not have the luxury of waiting to see how the competitive dynamics resolve. They will return Thursday. They will return Saturday. And the two companies that built their dominance on that structural necessity will continue, for the foreseeable future, to define the terms of their care.

March 3, 2026, by a collective of authors at MMCG Invest, LLC, feasibility study consultant, serving USDA feasibility studies

Sources:

1.  United States Renal Data System (USRDS) — 2025 Annual Data Report

Epidemiology of Kidney Disease in the United States. NIDDK/NIH, December 2025.

URL: https://usrds-adr.niddk.nih.gov/2025/introduction

2.  Medicare Payment Advisory Commission (MedPAC) — Chapter 5: Outpatient Dialysis Services

Report to Congress: Medicare Payment Policy. March 2025.

URL: https://www.medpac.gov/wp-content/uploads/2025/03/Mar25_Ch5_MedPAC_Report_To_Congress_SEC.pdf

3.  Xia X, Deng W, Eliason PJ, et al. — Financial Ties, Market Structure, Commercial Prices, and Medical Director Compensation in Dialysis

JAMA Health Forum, 2025. Open access via PubMed Central.

URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC12177639/

4.  National Kidney Foundation (NKF) — Kidney Disease: Fact Sheet

Key statistics on CKD prevalence, ESRD incidence, racial disparities, and Medicare expenditure. NKF, 2024.

URL: https://www.kidney.org/about/kidney-disease-fact-sheet

5.  Centers for Medicare & Medicaid Services (CMS) — CY 2026 ESRD Prospective Payment System Final Rule

CMS-1830-F Fact Sheet. November 2025. Base rate $281.71/treatment effective January 1, 2026.

URL: https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2026-end-stage-renal-disease-esrd-prospective-payment-system-final-rule

6.  Koukounas KG, Thorsness R, Patzer RE, Wilk AS, et al. — Social Risk and Dialysis Facility Performance in the First Year of the ESRD Treatment Choices Model

Journal of the American Medical Association (JAMA), 2024. Open access via PubMed Central (PMC10777251).

URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC10777251/

7.  Rosner MH, Manley CR, Hickey EV III, Berns JS — Stakeholder Theory and For-Profit Dialysis: A Call for Greater Accountability

Clinical Journal of the American Society of Nephrology (CJASN), Vol. 18, Issue 9, September 2023. Open access via PubMed Central (PMC10564339).

URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC10564339/